{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:52:26Z","timestamp":1792601546142,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is a rare and severe adverse drug reaction (ADR) commonly seen in people taking drugs prescribed for metastatic cancer and osteoporosis. Prior studies only analyzed this ADR utilizing the public database Food and Drug Administration Adverse Event Reporting System (FAERS) by different stages (2010-2014, 2015-2021); a more comprehensive study is needed to analyze the MRONJ cases and the associated drugs from a longer time span. We conducted a retrospective pharmacovigilance analysis for all reported MRONJ cases between 2010 and 2023 in FAERS, using preferred terms and the primary suspect drug as searching conditions. Thus, this study aimed to analyze the MRONJ cases and the associated drugs more comprehensively. The reporting odds ratios (RORs) and 95% CIs were calculated for each queried drug. To distinguish the signal levels, we calculated the expected information component (EIC) and its 95% CI, using the Bayesian confidence propagation neural network (BCPNN) methods. We identified 22\u2009846 MRONJ cases. A total of 15 drug classes including 30 suspect drugs showed different positive signal levels; among these drugs, 8, 5, and 17 had strong, medium, and weak intensity signals (+++, ++, and +), respectively. Drug classes involved bisphosphonate, RANKL inhibitor, radiotherapy drug, monoclonal antibody for cancer, corticosteroid, tyrosine kinase inhibitor, mammalian target of rapamycin inhibitor, aromatase inhibitor, cyclin-dependent kinase 4\/6 inhibitor, immunomodulator, microtubule inhibitor, selective estrogen receptor modulator, sclerostin monoclonal antibody, estrogen receptor antagonist, and cytotoxic drug. Bisphosphonate, RANKL inhibitor, and radiotherapy drug exhibited higher risk than other classes with higher ROR or EIC 95% CI lower limit. Females had higher MRONJ incidence than males, and the mean age was 67.33\u2009\u00b1\u200911.71\u00a0yr. Compared with previous research, this study identified more drug classes and more novel medications with positive MRONJ signals that warrant further attention.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf003","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T18:28:33Z","timestamp":1736533713000},"source":"Crossref","is-referenced-by-count":11,"title":["Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7237-4169","authenticated-orcid":false,"given":"Yuhao","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Oral, Plastic, and Aesthetic Surgery, Hospital of Stomatology, Jilin University , Changchun 130021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2014Head and Neck Surgery, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yin","sequence":"additional","affiliation":[{"name":"Information Center, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oral, Plastic, and Aesthetic Surgery, Hospital of Stomatology, Jilin University , Changchun 130021 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[{"name":"Information Center, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]},{"name":"Guangdong Key Laboratory of Blockchain Security, Guangzhou University , Guangzhou 510006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"issue":"5","key":"2025022505582919200_ref1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the Jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"2025022505582919200_ref2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025022505582919200_ref3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"2025022505582919200_ref4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","article-title":"Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals","volume":"42","author":"Neha","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"2025022505582919200_ref5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/ijc.34962","article-title":"Association between CDK4\/6 inhibitors and drug-related osteonecrosis of the jaw: a pharmacoepidemiological study using the FDA Adverse Events Reporting System","volume":"155","author":"Go","year":"2024","journal-title":"Int J Cancer"},{"issue":"4","key":"2025022505582919200_ref6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"2025022505582919200_ref7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"2025022505582919200_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"2025022505582919200_ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.892503","article-title":"Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"2025022505582919200_ref10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: a systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis"},{"issue":"8-9","key":"2025022505582919200_ref11","doi-asserted-by":"publisher","DOI":"10.1002\/dvg.23500","article-title":"Medication-related osteonecrosis of the jaw: a literature review and update","volume":"60","author":"Kuroshima","year":"2022","journal-title":"Genesis"},{"issue":"5","key":"2025022505582919200_ref12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025022505582919200_ref13","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41598-020-80622-5","article-title":"Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw","volume":"11","author":"Kuo","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"2025022505582919200_ref14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/jbmr.2490","article-title":"OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice","volume":"30","author":"de Molon","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025022505582919200_ref15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/0022034520986804","article-title":"Antiresorptive-type and discontinuation-timing affect ONJ burden","volume":"100","author":"Hadaya","year":"2021","journal-title":"J Dent Res"},{"key":"2025022505582919200_ref16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bone.2019.03.031","article-title":"Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ)","volume":"123","author":"Gkouveris","year":"2019","journal-title":"Bone"},{"issue":"8","key":"2025022505582919200_ref17","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025022505582919200_ref18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"18","key":"2025022505582919200_ref19","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1200\/JCO.2005.05.064","article-title":"Cyclin D1 in breast cancer pathogenesis","volume":"23","author":"Arnold","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025022505582919200_ref20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"10226","key":"2025022505582919200_ref21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2025022505582919200_ref22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/curroncol31010016","article-title":"Relationship between medication-related osteonecrosis of the jaw and CDK4\/6 inhibitors in breast cancer","volume":"31","author":"Sen\u00edn","year":"2024","journal-title":"Curr Oncol"},{"key":"2025022505582919200_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104725","article-title":"Osteonecrosis of the jaw induced by arsenic trioxide therapy in a leukemia patient: a rare case report and literature review","volume":"109","author":"Derache","year":"2020","journal-title":"Oral Oncol"},{"key":"2025022505582919200_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.06.024","article-title":"Medication related osteonecrosis of jaw in a leukemia patient undergoing systemic arsenic trioxide therapy: a rare case report","volume":"99","author":"Kumar","year":"2019","journal-title":"Oral Oncol"},{"issue":"4","key":"2025022505582919200_ref25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2025022505582919200_ref26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"2025022505582919200_ref27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bjoms.2019.05.017","article-title":"Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report","volume":"57","author":"Akkach","year":"2019","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"14","key":"2025022505582919200_ref28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2025022505582919200_ref29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2025022505582919200_ref30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S8756-3282(01)00685-8","article-title":"The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro","volume":"30","author":"Taranta","year":"2002","journal-title":"Bone"},{"issue":"26","key":"2025022505582919200_ref31","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198606263142605","article-title":"Involutional osteoporosis","volume":"314","author":"Riggs","year":"1986","journal-title":"N Engl J Med"},{"issue":"2","key":"2025022505582919200_ref32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12020-011-9580-0","article-title":"Glucocorticoid-induced osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrine"},{"issue":"1","key":"2025022505582919200_ref33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025022505582919200_ref34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"13","key":"2025022505582919200_ref35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jnci\/djm025","article-title":"Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis","volume":"99","author":"Wilkinson","year":"2007","journal-title":"J Natl Cancer Inst"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf003\/61410300\/ziaf003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/3\/ziaf003\/61410300\/ziaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/3\/ziaf003\/61410300\/ziaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:58:44Z","timestamp":1740463124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf003\/7951395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf003","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,10]]},"article-number":"ziaf003"}}